Xintela AB (publ) (STO:XINT)
0.1900
+0.0015 (0.80%)
Jul 24, 2026, 5:12 PM CET
Xintela AB Market Cap
Xintela AB has a market cap or net worth of 163.64 million as of July 24, 2026. Its market cap has decreased by -37.46% in one year.
Market Cap
163.64M
Enterprise Value
175.63M
Revenue
2.59M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.19
ChartMarket Cap Chart
Since March 22, 2016, Xintela AB's market cap has increased from 103.68M to 163.64M, an increase of 57.83%. That is a compound annual growth rate of 4.51%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 24, 2026 | 163.64M | -17.63% |
| Dec 30, 2025 | 198.68M | 5.85% |
| Dec 30, 2024 | 187.69M | 26.87% |
| Dec 29, 2023 | 147.94M | -1.74% |
| Dec 30, 2022 | 150.56M | -26.24% |
| Dec 30, 2021 | 204.12M | 2.23% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Xbrane Biopharma AB | 209.14M |
| IRLAB Therapeutics AB | 189.46M |
| Simris Group AB (PUBL) | 174.12M |
| Elicera Therapeutics AB | 173.18M |
| Initiator Pharma | 166.34M |
| Diamyd Medical AB | 159.63M |
| Alzinova AB | 151.98M |
| Biovica International AB | 143.04M |